drugset / Trial / NCT01731886
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
Timeline
- Start
- 2012-09
- Primary completion
- 2017-04-11
- Completion
- 2017-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexamethasone | Small molecule | 40 mg | Oral |
| Comparator | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Comparator | Melphalan | Small molecule | 200 mg/m2 | Intravenous |
| Comparator | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | 4000 mg/m2 | Intravenous |
| Comparator | filgrastim | Protein / enzyme biologic | — | Subcutaneous |